Acquired Company

Alkermes completed the acquisition of Avadel Pharmaceuticals on 2/12/2026, acquiring Avadel via a court-approved scheme and Avadel became a wholly owned subsidiary of Alkermes for $21.00 per share in cash plus a contingent value right of up to $1.50 per share.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc. Show more

10 Earlsfort Terrace, Ballycoolin, Dublin, D02 T380, Ireland

https://www.avadel.com

Drug Manufacturers - Specialty & Generic

Healthcare

Start AI Chat

Market Cap

2.124B

52 Wk Range

$6.38 - $23.57

Previous Close

$21.64

Open

$21.64

Volume

200

Day Range

$21.64 - $21.64

Enterprise Value

2.035B

Cash

91.58M

Avg Qtr Burn

N/A

Insider Ownership

1.13%

Institutional Own.

86.80%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LUMRYZ (sodium oxybate) Details Excessive daytime sleepiness, Narcolepsy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (sodium oxybate) Details Narcolepsy, Excessive daytime sleepiness, Cataplexy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (sodium oxybate) Details Idiopathic hypersomnia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.